Hormonal receptor positive breast cancer adjuvant and metastatic indications
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Uncommon genetic aberrations NTRK, RET, NRG
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
ASCO 2024: Lung cancer highlights
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM